Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma

Mucosal melanoma is rare and accounts for 1.3–1.4% of all melanomas. Kit mutations are found in approximately 15–20% of mucosal melanomas. Immunotherapy with anti cytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death protein 1 have reported low clinical efficacy in this melanoma subtype. Studies with Kit inhibitor Imatinib showed response rates ranging from 20 to 30%. We present the case of a patient with a c-kit mutated metastatic melanoma who developed autoimmune vitiligo during treatment with oral tyrosine kinase inhibitor Masitinib.